How to Get Enclomiphene Citrate in New Jersey

What Is Enclomiphene Citrate and Why New Jersey Patients Request It

Enclomiphene is the trans-isomer of clomiphene, and it works by blocking estrogen receptors at the hypothalamus to raise LH and FSH, which in turn stimulates the testes to produce more testosterone. Unlike testosterone replacement therapy (TRT), enclomiphene preserves sperm production and keeps the hypothalamic-pituitary-gonadal axis intact. That profile is why men who want to maintain fertility while treating secondary hypogonadism frequently ask their providers about it.

The compound is not currently FDA-approved as a standalone drug for male hypogonadism. Androxal, an enclomiphene product developed by Repros Therapeutics, completed Phase III trials but did not receive final FDA approval for secondary hypogonadism. The FDA complete response letter history is documented on the agency's drug database. Because no finished, FDA-approved oral enclomiphene product is commercially available for this indication, patients in New Jersey obtain it exclusively through 503A compounding pharmacies operating under a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies.

Kim et al. published a randomized controlled trial in BJU International (2016, N=124) showing that enclomiphene citrate normalized serum testosterone in 85% of men with secondary hypogonadism while preserving spermatogenesis, compared with testosterone gel, which suppressed sperm counts significantly. That trial is indexed on PubMed. New Jersey providers cite this data regularly when justifying off-label prescriptions.

A 2013 Phase II study by Wiehle et al. found that 25 mg enclomiphene raised mean total testosterone from 237 ng/dL to 412 ng/dL over 3 months in men with secondary hypogonadism, a statistically significant increase (P<0.001). That study is available on PubMed. Those numbers give New Jersey prescribers a reasonable efficacy benchmark when counseling patients on expected response.

New Jersey Legal Framework for Prescribing Enclomiphene Citrate

New Jersey permits telehealth prescribing of controlled and non-controlled substances, and enclomiphene is not a controlled substance, which simplifies the process considerably. The New Jersey Division of Consumer Affairs governs prescribing via telemedicine under N.J.A.C. 13:35-6.4, which requires that a valid prescriber-patient relationship be established before any prescription is issued. A single synchronous video visit satisfies that requirement in most cases.

New Jersey's telehealth law, updated in 2021 under P.L. 2021, c. 134, mandates that prescribers hold an active New Jersey license regardless of where they are physically located when treating a patient physically present in the state. The New Jersey Board of Medical Examiners publishes licensure requirements on their Division of Consumer Affairs portal.

503A compounding pharmacies located in New Jersey, or licensed to ship into New Jersey, may legally dispense enclomiphene citrate in oral capsule or tablet form. The pharmacy must receive a patient-specific prescription, cannot advertise the product as a commercial alternative to an FDA-approved drug, and must compound in compliance with USP Chapter 795 standards for non-sterile preparations. USP 795 standards are referenced in FDA guidance here.

Who Can Prescribe Enclomiphene Citrate in New Jersey

Any licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) holding an active New Jersey prescribing license may write an enclomiphene prescription. NPs in New Jersey practice under full prescriptive authority without physician oversight, following 2018 legislation that granted independent practice. The New Jersey Board of Nursing outlines NP prescribing scope here.

PAs in New Jersey prescribe under a collaborative agreement with a supervising physician, but that agreement does not restrict which off-label medications they may order as long as the prescription falls within their area of competency. Endocrinologists, urologists, and men's health-focused primary care physicians are the most common prescribers in New Jersey for this indication. Telehealth platforms that specialize in hormone health typically employ NPs or PAs supervised by MDs, and all of those configurations are legally valid in New Jersey.

The table below summarizes NJ prescriber types and their authority for enclomiphene:

| Prescriber Type | Independent Rx Authority in NJ | Notes | |---|---|---| | MD / DO | Yes | No restrictions on off-label prescribing | | NP (APRN) | Yes (since 2018) | Full independent prescriptive authority | | PA | Collaborative | Requires supervising MD collaborative agreement | | Naturopath (ND) | No | NDs do not hold Rx authority in NJ |

Required Labs Before an NJ Provider Will Prescribe Enclomiphene Citrate

Baseline bloodwork is non-negotiable. New Jersey providers typically require the following panel before writing the first prescription:

• Total testosterone (morning draw, 7 to 10 a.m., two separate readings on different days per Endocrine Society guidelines)
• LH (luteinizing hormone)
• FSH (follicle-stimulating hormone)
• Estradiol (E2)
• Complete metabolic panel (CMP)
• CBC (complete blood count)
• PSA (prostate-specific antigen) in men over 40

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states that "the diagnosis of androgen deficiency requires the presence of symptoms and signs consistent with testosterone deficiency and unequivocally low serum testosterone concentrations." That guideline is published in the Journal of Clinical Endocrinology and Metabolism. Two morning total testosterone measurements below 300 ng/dL, combined with elevated or normal LH, confirm secondary hypogonadism and support the prescribing decision.

Some NJ telehealth providers accept recent lab results (within 60 to 90 days) from a primary care physician or LabCorp or Quest location. Others require you to complete a new draw through their own requisition. Confirming that policy before booking the consultation saves time. Quest Diagnostics and LabCorp both operate patient service centers throughout NJ; ordering testosterone panels directly is covered under the NJ Direct Access Testing law.

Repeat labs at 6 to 8 weeks on therapy are standard practice. A well-conducted follow-up panel should include total testosterone, LH, FSH, and estradiol. If testosterone remains below 300 ng/dL, the prescriber may increase the dose from 12.5 mg to 25 mg. Dose titration guidance is consistent with the pharmacokinetic data published on PubMed for enclomiphene.

Step-by-Step Process: Getting Enclomiphene in New Jersey via Telehealth

Step 1. Select a licensed NJ telehealth provider. Confirm the platform's prescriber holds an active New Jersey medical or advanced practice license. The NJ Division of Consumer Affairs license lookup tool verifies this in under two minutes. License verification is available at the NJDCA portal.

Step 2. Complete the intake form and medical history. Most platforms collect symptoms (fatigue, low libido, brain fog, decreased morning erections), prior hormone history, current medications, and any relevant diagnoses. Honest disclosure of prior TRT use matters here. Exogenous testosterone suppresses LH, so a provider needs to know if LH suppression is TRT-related rather than idiopathic.

Step 3. Order baseline labs. The platform sends a requisition to LabCorp or Quest. New Jersey has dozens of draw sites in Newark, Jersey City, Trenton, Cherry Hill, and across the state. Fasted morning draws are preferred for testosterone accuracy. The Endocrine Society recommends morning collection for testosterone measurement.

Step 4. Attend the video consultation. A synchronous video visit satisfies NJ's prescriber-patient relationship requirement. The visit typically runs 20 to 30 minutes. The prescriber reviews your labs, symptoms, and goals, and decides on the starting dose.

Step 5. Rx sent to a 503A compounding pharmacy. The prescription goes to a licensed 503A pharmacy. Many compound enclomiphene as 12.5 mg or 25 mg oral capsules. Shipping to any NJ address is permitted. FDA oversight of 503A pharmacies is documented on the FDA compounding page.

Step 6. Receive medication and begin therapy. Standard shipping from most compounding pharmacies to NJ addresses takes 3 to 5 business days. Total time from completing labs to receiving medication is typically 5 to 7 business days, assuming no insurance prior authorization is needed.

Step 7. Follow-up labs at week 6 to 8. Repeat total testosterone, LH, FSH, and estradiol. The prescriber adjusts dose or confirms continuation based on response and symptom trajectory.

Enclomiphene Citrate Telehealth Providers Serving New Jersey

Several national and regional telehealth platforms are licensed to prescribe in New Jersey. When evaluating a platform, confirm three things: the prescriber's active NJ license, the affiliated pharmacy's 503A licensure, and the follow-up lab monitoring protocol.

Platforms that operate only asynchronous questionnaire models (no video visit) may not satisfy NJ's prescriber-patient relationship requirement. Avoid platforms that skip baseline labs or offer a prescription without reviewing testosterone values. That shortcut is a red flag for both clinical safety and regulatory compliance.

HealthRX operates with NJ-licensed prescribers, mandatory baseline labs, and a supervised compounding pharmacy network. The clinical team follows the Endocrine Society hypogonadism guideline for diagnostic thresholds and monitors patients at 6-week intervals. The Endocrine Society guideline sets the clinical standard for this approach.

503A Compounding Pharmacies in New Jersey

503A pharmacies in New Jersey are licensed by the New Jersey Board of Pharmacy and may also be accredited by the Pharmacy Compounding Accreditation Board (PCAB). When a NJ pharmacy compounds enclomiphene, it must do so based on a valid patient-specific prescription, not in bulk anticipation of demand. The FDA distinguishes 503A from 503B outsourcing facilities here.

Oral enclomiphene capsules are the most common dosage form in 503A pharmacies, compounded in 12.5 mg and 25 mg strengths. Some pharmacies also prepare sublingual troches, though bioavailability data for this route is limited. Capsule formulations are the standard referenced in published clinical trial data.

Beyond-use dating (BUD) for non-sterile oral solids under USP 795 is typically 180 days when compounded with appropriate stability data. This means a 90-day supply dispensed at a 503A pharmacy remains within BUD for the full treatment course. USP Chapter 795 BUD requirements are codified in FDA guidance.

Patients outside a New Jersey 503A pharmacy's service area may receive shipments from out-of-state 503A pharmacies, provided the pharmacy holds a valid New Jersey non-resident pharmacy license. New Jersey requires out-of-state pharmacies to register with the NJ Board of Pharmacy before shipping into the state. The NJ Board of Pharmacy issues non-resident pharmacy licenses.

NJ Medicaid Prior Authorization for Enclomiphene Citrate

New Jersey Medicaid covers enclomiphene citrate for secondary hypogonadism with prior authorization (PA). The prior authorization process requires documentation of the following:

1. Two morning total testosterone values below 300 ng/dL drawn at least one week apart
2. LH and FSH results confirming the secondary (central) origin of hypogonadism
3. Clinical notes documenting symptoms consistent with testosterone deficiency
4. Prescriber attestation that the indication is secondary (not primary) hypogonadism
5. Confirmation that the patient has not responded to or is not a candidate for standard testosterone replacement

The PA request is submitted by the prescriber or the pharmacy on the prescriber's behalf. NJ FamilyCare (the state's Medicaid program) processes PA requests within 3 business days for standard reviews and 24 hours for urgent clinical situations. NJ FamilyCare prior authorization procedures are published by the New Jersey Division of Medical Assistance and Health Services.

If PA is denied, the prescriber may file a level-one appeal within 30 days of the denial notice. Providing peer-reviewed trial data, specifically the Kim et al. 2016 BJU International paper, strengthens the medical necessity argument considerably. That trial abstract is on PubMed.

Commercial insurance coverage varies widely. Most commercial plans in New Jersey do not cover compounded medications without specific policy riders. Patients paying out of pocket typically spend $60 to $150 per month depending on pharmacy and dose.

Transferring an Enclomiphene Prescription to New Jersey

If you received an enclomiphene prescription from a provider licensed in another state and you move to or travel to New Jersey, the prescription transfer rules depend on whether the originating pharmacy holds a NJ non-resident pharmacy license.

A prescription from an out-of-state prescriber is valid in New Jersey only if the prescriber holds a valid license in the state where the patient-provider relationship was established, AND the pharmacy dispensing the medication is registered to ship into NJ. If you relocate permanently, the safest path is to establish care with a NJ-licensed prescriber who can issue a new NJ prescription, rather than relying on an out-of-state Rx. NJ pharmacy law governing prescription transfers is administered by the Board of Pharmacy.

One practical note: since enclomiphene is not a controlled substance, there is no DEA scheduling restriction on transfers. This is one area where enclomiphene has a meaningful administrative advantage over testosterone cypionate, which is Schedule III and carries additional transfer restrictions.

Typical Dosing Protocol for Enclomiphene Citrate in New Jersey Practices

NJ prescribers follow a dose range broadly consistent with published trial data. The Kim et al. 2016 study used 12.5 mg and 25 mg once-daily oral dosing and demonstrated testosterone normalization at both doses, with the 25 mg cohort showing greater mean increases (from 237 ng/dL to approximately 450 ng/dL at 12 weeks). Full trial data at PubMed.

Standard NJ protocol:

• Weeks 1 to 6: 12.5 mg once daily (starting dose, assess tolerability)
• Week 6 to 8 labs: Total testosterone, LH, FSH, estradiol
• If testosterone remains <300 ng/dL: Increase to 25 mg once daily
• Week 12 to 14 labs: Confirm testosterone response, check estradiol for elevation
• Ongoing: Quarterly labs, annual PSA in men over 40

Elevated estradiol is the most common side effect requiring management. Enclomiphene's mechanism (estrogen receptor blockade at the hypothalamus) does not prevent peripheral aromatization, so serum estradiol may rise alongside testosterone. If estradiol exceeds 40 pg/mL with symptoms, providers sometimes add a low-dose aromatase inhibitor. The hormonal axis interactions are described in endocrine literature indexed on PubMed.

Visual disturbances, a known clomiphene class effect, occur at a lower rate with enclomiphene than with racemic clomiphene citrate, because the visual side effects are largely attributed to the zuclomiphene isomer. Patients should still report any changes in vision promptly. FDA drug safety information is maintained on the FDA portal.

Enclomiphene vs. TRT: Why Some NJ Men Choose Enclomiphene

TRT (testosterone cypionate, enanthate, or topical gel) directly replaces testosterone but suppresses endogenous LH and FSH within weeks, leading to testicular atrophy and azoospermia or severe oligospermia in most men. For men in their late 20s to early 40s who want to preserve fertility options, that trade-off is often unacceptable.

A 2013 head-to-head comparison published in the International Journal of Impotence Research found that enclomiphene raised testosterone comparably to topical testosterone gel while preserving sperm counts, where gel therapy produced a mean sperm count decline of approximately 70% at 26 weeks. That comparison data is indexed on PubMed.

The American Urological Association's 2018 guideline on male infertility lists clomiphene citrate as an option for empiric treatment of non-obstructive male infertility. Enclomiphene, as the more selective isomer, is used analogously in clinical practice. AUA guideline resources are available through academic repositories.

Men who have already used TRT and suppressed their HPG axis require a different approach. HCG (human chorionic gonadotropin) or a combination protocol may be needed first to restart endogenous LH signaling before enclomiphene becomes effective. NJ prescribers experienced in hormone therapy recognize this distinction; a provider who does not ask about prior TRT history is worth reconsidering.

Cost of Enclomiphene Citrate in New Jersey

Compounded enclomiphene citrate in New Jersey generally costs between $60 and $150 per month for a 30-day supply at 12.5 mg to 25 mg daily. Pricing varies by pharmacy, capsule count, and whether the platform charges a separate consultation fee.

Most NJ commercial insurance plans classify compounded medications as non-covered, meaning the patient pays cash price. NJ Medicaid covers enclomiphene with prior authorization as described above, which can reduce or eliminate out-of-pocket cost for eligible patients. NJ FamilyCare program details are on the DMAHS site.

Telehealth consultation fees in NJ range from $0 (subscription model) to $150 per visit. Lab fees at LabCorp or Quest for the baseline testosterone panel run $80 to $200 without insurance. Some platforms bundle labs into a subscription that covers consultation, labs, and medication for a flat monthly fee of $150 to $250.